Stability: Formulations that protect the fragile molecules from light and air
Non combinare con altri stimolanti della secrezione insulinica senza parere medico
Q: Were constantly bombarded with ads for these GLP-1 drugs
In a 26-week phase 2 study involving patients with obesity and T2DM, treatment with tirzepatide dose-dependently decreased the circulating levels of specific biomarkers of inflammation and endothelial dysfunction previously associated with cardiovascular events, suggesting a net improvement in the cardiovascular risk profile of these patients.37 In this post hoc analysis, inflammation, endothelial dysfunction, and cellular stress biomarkers were measured at baseline and 4, 12, and 26 weeks to evaluate the additional effects of tirzepatide on cardiovascular risk factors.37 After 26 weeks, tirzepatide treatment at doses of 10 and 15 mg decreased the levels of YKL-40 (also known as chitinase-3 like-protein-1), intercellular adhesion molecule 1 (ICAM-1), leptin, and growth differentiation factor 15 compared with baseline
Anyone claiming Lipo C 'melts fat' without mentioning caloric deficit is selling you marketing, not medicine
